Skip to content

Study · Animal study (in vivo) · mouse · 2004

5 results

Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze.

Alcalay RN, Giladi E, Pick CG, Gozes I

Neuroscience letters1 May 2004Cited by 68 (Europe PMC)

PMID15135910 (opens in a new tab)DOI10.1016/j.neulet.2003.12.005 (opens in a new tab)PepBankPUB-15135910
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, daily intranasal NAP reduced anxiety as measured by open-arm time after 5 months.

    In plain wordsIn mice, daily intranasal NAP reduced anxiety measured by time in open maze arms after 5 months.

    Peptide
    Davunetide
    Outcome
    DecreaseAnxiety-like behavior at 5 months measured by open-arm time
    Study

    mousen: not reported in source

    Aging mice
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 5 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Results showed that 5 months of daily (intranasal) treatment with NAP reduced anxiety, measured as the percentage of time spent in the open arms of the maze (P < 0.01).
    1 context sentence
    Summary · context
    Therefore, we have tested here the effects of chronic NAP treatment on anxiety-like behavior in mice in the elevated plus maze.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, the NAP-associated reduction in anxiety measured by open-arm time persisted after 8 months.

    In plain wordsIn mice, NAP's effect on anxiety measured by open-arm time persisted after 8 months.

    Peptide
    Davunetide
    Outcome
    DecreaseAnxiety-like behavior at 8 months measured by open-arm time
    Study

    mousen: not reported in source

    Aging mice
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 8 monthsAs given in this study (mouse).

    Source sentences

    Summary
    This effect was maintained after a longer (8 months) exposure to NAP.
    2 context sentences
    Summary · context
    Results showed that 5 months of daily (intranasal) treatment with NAP reduced anxiety, measured as the percentage of time spent in the open arms of the maze (P < 0.01).
    Summary · context
    Therefore, we have tested here the effects of chronic NAP treatment on anxiety-like behavior in mice in the elevated plus maze.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, NAP increased the proportion of open-arm entries after 8 months of treatment.

    In plain wordsIn mice, NAP increased the proportion of entries into open maze arms after 8 months.

    Peptide
    Davunetide
    Outcome
    IncreaseProportion of open-arm entries
    Study

    mousen: not reported in source

    Aging mice
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 8 monthsAs given in this study (mouse).

    Source sentences

    Summary
    In addition, after 8 months of NAP treatment, the percentage of open arm entries out of total arms entries was significantly higher in the treated mice ( P < 0.01).
    1 context sentence
    Summary · context
    Therefore, we have tested here the effects of chronic NAP treatment on anxiety-like behavior in mice in the elevated plus maze.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, motor function indices did not differ significantly between NAP-treated and comparison groups.

    In plain wordsIn mice, motor function did not differ significantly between NAP-treated and comparison groups.

    Peptide
    Davunetide
    Outcome
    No significant changeMotor function indices
    Study

    mousen: not reported in source

    Aging mice
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · intranasalAs given in this study (mouse).

    Source sentences

    Summary
    Motor function indices indicated no significant differences between the groups.
    1 context sentence
    Summary · context
    Therefore, we have tested here the effects of chronic NAP treatment on anxiety-like behavior in mice in the elevated plus maze.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In aging mice, NAP treatment showed some beneficial effects on Morris water maze performance after 7 months.

    In plain wordsIn aging mice, NAP showed some benefits for water maze performance after 7 months.

    Peptide
    Davunetide
    Outcome
    IncreaseMorris water maze performance
    Study

    mousen: not reported in source

    Aging mice
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 7 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, prolonged treatment with NAP (7 months) showed some beneficial effects on Morris water maze performance in the aging mice.
    1 context sentence
    Summary · context
    Therefore, we have tested here the effects of chronic NAP treatment on anxiety-like behavior in mice in the elevated plus maze.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00505765

A Multicenter Study of NAP (AL-108) in Schizophrenia

University of California, Los Angelesn = 63Jul 2007 to Apr 2009

Schizophrenia

Trial pageClinicalTrials.govUpdated 10 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.